Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 13;3(9):e954925.
doi: 10.4161/21624011.2014.954925. eCollection 2014 Oct.

Using α radiation to boost cancer immunity?

Jean-Baptiste Gorin  1 , Yannick Guilloux  1 , Alfred Morgenstern  2 , Michel Chérel  3 , François Davodeau  1 , Joëlle Gaschet  1
Affiliations

Using α radiation to boost cancer immunity?

Jean-Baptiste Gorin et al. Oncoimmunology. .

Abstract

Radioimmunotherapy aims to deliver radiation directly to cancer cells by means of a tumor specific vector coupled to a radionuclide. Alpha radionuclides are very potent agents to treat disseminated cancer and metastasis. We have demonstrated that α radiation can also induce immunogenic cell death, reinforcing interest in their clinical development.

Keywords: 213Bi, bismuth-213; 224Ra, radium-224; DAMPs, danger associated molecular patterns; DC, dendritic cells; HMGB1, high mobility group box 1; Hsp70, 70 kilodalton heat shock protein; RIT; RIT, radioimmunotherapy; abscopal effect; cancer; immunogenic cell death; ionizing radiation; α emitters.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The radionuclide 213Bi induces immunogenic cell death that fosters effective antitumor immune protection in vivo. 213Bi irradiation of MC-38 adenocarcinoma cells causes them to release danger associated molecular proteins (DAMPs) such as heat shock protein 70 (HSP70) and high mobility group box 1 (HMGB1), thus activating dendritic cells (DCs). Activated DCs express costimulatory molecules that allow the activation of cytotoxic T cells specific for tumor antigens. T cells can then migrate in the body and eliminate remaining tumor cells at distant sites.
See this image and copyright information in PMC

References

    1. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G, et al. . MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010; 5:311-28; PMID: ; http://dx.doi.org/10.2967/jnumed.108.058651 - DOI - PMC - PubMed
    1. Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res 2013; 19:530-7; PMID: ; http://dx.doi.org/10.1158/1078-0432.CCR-12-0298 - DOI - PMC - PubMed
    1. Chérel M, Gouard S, Gaschet J, Saï-Maurel C, Bruchertseifer F, Morgenstern A, Bourgeois M, Gestin JF, Bodéré FK, Barbet J, et al. . 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med 2013; 54:1597-604; PMID: ; http://dx.doi.org/10.2967/jnumed.112.111997 - DOI - PubMed
    1. Golden EB, Formenti SC. Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology 2014; 3:e28133; PMID: ; http://dx.doi.org/10.4161/onci.28133 - DOI - PMC - PubMed
    1. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105:256-65; PMID: ; http://dx.doi.org/10.1093/jnci/djs629 - DOI - PMC - PubMed

LinkOut - more resources